Beijing Scitop Bio-tech Co (300858) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 reached ¥163.35 million, up 18.32% year-over-year, while net profit attributable to shareholders was ¥41.21 million, down 5.31% year-over-year.

• Core business in probiotics and microecological products continued to expand, with animal and plant microecological products revenue up 83.12% year-over-year.

• The company invested in new production bases and R&D, and participated in national standards and key R&D projects, reinforcing its industry leadership.

• No interim dividend, bonus shares, or capital increase from reserves was planned for the period.

Financial highlights

• Operating income: ¥163.35 million (+18.32% YoY); net profit: ¥41.21 million (–5.31% YoY); basic EPS: ¥0.16 (–5.88% YoY).

• Cash flow from operations: ¥27.88 million (–44.47% YoY); total assets: ¥1.94 billion (+1.46% from year-end 2024).

• Gross margin for core probiotic products was 60.02%; animal and plant microecological products margin was 18.72%.

• Non-recurring items (mainly government grants and fair value changes) contributed ¥6.08 million to profit.

Outlook and guidance

• Management expects continued growth in probiotic demand, with the company positioned to benefit from industry expansion and health trends.

• Ongoing investment in production and R&D capacity, with the main new food production base expected to be operational by end-2025.